Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Intas Pharmaceuticals Limited
483
•Intas Pharmaceuticals Limited•December 2, 2022

Intas Pharmaceuticals Limited – FDA 483, Dec 2, 2022

Record Details

The FDA Form 483 documents multiple violations at an unnamed facility, indicating significant deficiencies in laboratory practices, quality control, and manufacturing processes.

**Laboratory and Quality Control Issues:** * **Incomplete Data:** Laboratory records lack complete data from tests necessary for specification compliance. * **Inaccurate Environmental Monitoring:** Environmental monitoring samples were inaccurately counted, with reported results less than actual colony counts. A practice of counting merged colonies as one led to undercounting. * **Missing Raw Data:** Printouts, used as raw data, could not be provided for review during reconciliation of analysis performed on January 13, 2021, for instrument SC1111. * **Unfollowed Procedures:** Established test procedures and laboratory control mechanisms are not consistently followed. * **Uncontrolled Data Integration:** No procedure exists for manually entered integration events in chromatography data, and reviewers only examine final chromatograms, not original ones, to justify manual changes. * **Quality Unit Failure:** The Quality Control Unit's responsibilities and procedures are not fully followed, demonstrating a "cascade of failure" in managing GMP documents critical for drug product safety and effectiveness. * **Unvalidated Test Methods:** The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established. * **Inadequate Computer Controls:** Controls over computer systems are insufficient to ensure only authorized personnel institute changes to master production and control records.

**

Company
Intas Pharmaceuticals Limited
Inspection date
December 2, 2022
Office
Office of Pharmaceutical Quality Operations
People
  • Jose E. Melendez (Quality System Specialist)
  • Justin A. Boyd (Research Specialist II)
  • Pratik S. Upadhyay
View Company Profile

ID · aaef987c-6382-4641-8d0e-9fc48ace87ba

Violation Codes2
21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Intas Pharmaceuticals Limited
  • WARNING_LETTER - 2025-09-17September 17, 2025
  • 483 - 2025-02-14February 14, 2025
  • 483 - 2024-01-24January 24, 2024
  • 483 - 2023-12-07December 7, 2023
  • 483 - 2023-05-12May 12, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Intas Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.